Clinical trials
Brain Metastases From Breast Cancer clinical trials
Below are recruiting brain metastases from breast cancer clinical trials, each written for real people, not researchers. We’re tracking 365 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05575804RecruitingPhase 1/Phase 2
GQ1001 plus pyrotinib for HER2-positive metastatic breast cancer
This trial tests a combination of two targeted drugs, GQ1001 and pyrotinib, for people with HER2-positive breast cancer that has spread to other parts of the body and has not responded to at least one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT06555068RecruitingPhase 1/Phase 2
Study of HRS-6209 combinations for advanced breast cancer
This trial tests a new drug, HRS-6209, combined with different hormone treatments (fulvestrant, letrozole, HRS-8080, or HRS-1358) for people with advanced breast cancer that has spread or cannot be surgically removed and has worsened after previous treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Scottsdale, ArizonaAges 18 years+ - NCT06679036RecruitingPhase 1/Phase 2
Combination therapy for advanced breast cancer
This trial tests new drug combinations for advanced or metastatic breast cancer. It aims to see if adding HRS-2189, HRS-6209, or HRS-1358 to standard treatments works better. Participants must have tried certain hormone therapies or chemotherapies before.
Harbin, HeilongjiangAges 18–75 - NCT06770296RecruitingPhase 1
Finding the best dose of pyrotinib for first-line advanced HER2 breast cancer
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Nanjing, JiangsuAges 18–75 - NCT07498478RecruitingPhase 2
Tinengotinib and fulvestrant for advanced HR+ HER2- breast cancer
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT06016387RecruitingPhase 2
Drug combo with radiation for HER2+ breast cancer spread to spinal lining
This trial tests a combination of three targeted drugs (tucatinib, trastuzumab, and capecitabine) along with radiation to the brain or spine for people whose HER2-positive breast cancer has spread to the lining of the brain or spinal cord. The goal is to see if this treatment is safe and effective.
Ottawa, OntarioAges 18 years+ - NCT06240195Recruiting
Study of sacituzumab govitecan for advanced triple-negative breast cancer
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
Rome, RomeAges 18 years+ - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT04892693RecruitingPhase 2
Talazoparib for advanced breast cancer with DNA repair defects
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
SeoulAges 19 years+ - NCT05181033RecruitingPhase 2
Lenvatinib plus letrozole versus fulvestrant for metastatic breast cancer
This Phase 2 study compares a combination medicine (lenvatinib plus letrozole) against fulvestrant to treat metastatic estrogen-receptor positive, HER2-negative breast cancer after the cancer has grown despite hormone therapy plus a CDK4/6 inhibitor. It may help by finding a more effective treatment option after your first lines have stopped working.
SingaporeAges 18–99 - NCT06230055RecruitingPhase 4
Chemotherapy for breast cancer that has spread to the spinal fluid
This trial tests a chemotherapy drug given directly into the spinal fluid for people with HER2-negative breast cancer that has spread to the lining of the brain and spinal cord (called leptomeningeal metastasis). It may help when standard treatments have stopped working or caused too many side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06887088RecruitingPhase 2
Study of encorafenib, binimetinib, cemiplimab, and fianlimab for melanoma with brain metastases
This trial tests a combination of targeted drugs (encorafenib and binimetinib) followed by immunotherapy (cemiplimab and fianlimab) for people with advanced melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach can shrink tumors and help control the disease.
A Coruña, A CoruñaAges 18 years+ - NCT06994377Recruiting
Emotional distress study for newly treated metastatic breast cancer
This trial studies emotional distress in people with metastatic breast cancer who have not yet received treatment for their advanced disease. It explores how different standard first-line therapies affect emotional well-being.
AnconaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07260591RecruitingPhase 1
VSV-02 for advanced solid tumors that need new options
This trial tests an experimental virus therapy called VSV-02 for people with advanced solid tumors that have not responded to standard treatments. The treatment is given directly into a tumor, aiming to attack cancer from the inside.
Xinxiang, HenanAges 18 years+ - NCT06598046RecruitingPhase 2
Utidelone and Capecitabine for triple-negative breast cancer brain metastases
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Zhengzhou, HenanAges 18 years+ - NCT06399757RecruitingPhase 1/Phase 2
A study of APL-5125 for advanced solid tumors
This trial tests a new drug called APL-5125 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. If you have certain types of advanced cancer, this study may offer a new option.
Duarte, CaliforniaAges 18 years+ - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT04862663RecruitingPhase 3
Capivasertib plus hormone therapy for HR+ breast cancer after progression
This Phase 3 trial studies capivasertib (a targeted pill) plus fulvestrant (a hormone injection) together with a CDK4/6 inhibitor to treat HR+ / HER2- advanced breast cancer that has returned or grown despite earlier hormone therapy. It may help by blocking growth signals linked to cancer cell survival.
Tucson, ArizonaAges 18–99 - NCT06837792RecruitingPhase 2
T-DXd vs hormone therapy for HER2-low advanced breast cancer
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
SeoulAges 19 years+ - NCT04020575RecruitingPhase 1
CAR T cells made from your blood for advanced breast cancer
This Phase 1 trial tests CAR T cells made from your own immune cells to target advanced breast cancer. The cells are designed to recognize a specific cancer marker (called MUC1*), with the goal of shrinking tumors or keeping them under control.
Duarte, CaliforniaAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Orlando, FloridaAges 18 years+
Hear when a new Brain Metastases From Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for brain metastases from breast cancer?
- Yes. Clin2 currently lists 365 recruiting brain metastases from breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brain metastases from breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brain metastases from breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Brain Metastases From Solid Tumors
- Liver Metastases From Colorectal Cancer
- Peritoneal Metastases From Colorectal Cancer
- Brain Metastases From Extra-cranial Solid Tumors
- Triple Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.